Company Description
Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide.
The company offers On-X prosthetic aortic and mitral heart valves; On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters; Chord-X ePTFE sutures; pyrolytic carbon coating services; E-vita Open NEO, a hybrid stent graft; Arcevo, an LSA hybrid stent graft system; AMDS hybrid prosthesis; and NEXUS ONE, an endovascular stent graft system.
It also provides NEXUS DUO, an aortic arch system; NEXUS TRE, a custom-made three branch graft; E-vita thoracic 3G, a stent graft system; E-xtra Design Engineering, a range of stent graft systems for the treatment of aortic vascular diseases, such as TAAA and Artivex; E-nside, a multibranch stent graft system; E-tegra, an AAA stent graft system; E-ventus BX and Tuva BX balloon-expandable peripheral stent grafts; and E-liac, a stent graft used to treat aneurysmal iliac arteries.
In addition, the company offers synthetic vascular grafts that are used in open aortic and peripheral vascular surgical procedures; BioGlue, a surgical sealant; CryoValve SG pulmonary heart valve; CryoPatch SG pulmonary cardiac patch; SynerGraft, a decellularization technology; vascular preservation services; and PhotoFix, a bovine pericardial patch fixated.
It markets its products and preservation services primarily to physicians through a direct sales team to hospitals and other healthcare facilities.
The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022.
Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.
| Country | United States |
| Founded | 1984 |
| IPO Date | Feb 11, 1993 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 1,800 |
| CEO | James Mackin |
Contact Details
Address: 1655 Roberts Boulevard NW Kennesaw, Georgia 30144 United States | |
| Phone | 770 419 3355 |
| Website | artivion.com |
Stock Details
| Ticker Symbol | AORT |
| Exchange | NYSE |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000784199 |
| CUSIP Number | 228903100 |
| ISIN Number | US2289031005 |
| Employer ID | 59-2417093 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| James Patrick Mackin | Chairman, President and Chief Executive Officer |
| Lance A. Berry CPA | EVice President, Chief Operating Officer, Chief Financial Officer and Treasurer |
| Jean F. Holloway Esq. | Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary |
| John E. Davis | Senior Vice President and Chief Commercial Officer |
| Dr. Marshall S. Stanton M.D. | Senior Vice President of Clinical Research and Chief Medical Officer |
| Amy D. Horton CPA | Vice President and Chief Accounting Officer |
| Matthew A. Getz | Vice President of Human Resources and Chief Human Resources Officer |
| Jason D. Asper | Senior Vice President and Chief Strategy and Digital Officer |
| Andrew M. Green | Senior Vice President of Regulatory and Quality |
| Dr. Robert C. Thomson Ph.D. | Vice President of Research and Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 4, 2026 | 144 | Filing |
| Mar 3, 2026 | 144 | Filing |
| Mar 3, 2026 | 144 | Filing |
| Mar 3, 2026 | 144 | Filing |
| Mar 3, 2026 | 144 | Filing |
| Mar 3, 2026 | 144 | Filing |
| Mar 3, 2026 | 144 | Filing |
| Mar 2, 2026 | 144 | Filing |
| Mar 2, 2026 | 144 | Filing |
| Mar 2, 2026 | 144 | Filing |